abstract_id
stringlengths 8
8
| label
stringclasses 5
values | text
stringlengths 1
1.39k
| sentence_id
int64 0
30
|
|---|---|---|---|
24672940 | methods | The treatment period for the two groups was @ weeks . | 3 |
24672940 | methods | Patients were followed-up till the @th week . | 4 |
24672940 | methods | Clinical symptoms such as fever , lymphadenopathy and hepatosplenomegaly , as well as lab indices such as abnormal lymphocyte percentage , EB virus antibody , virus DNA load , T cell subsets , immunoglobulin , and so on were observed before and after treatment , at week @ and @ of follow-ups . | 5 |
24672940 | results | ( @ ) The total effective rate at week @ was @ % in the treatment group , higher than that of the control group ( @ % ) , but there was no statistical difference between the two groups . | 6 |
24672940 | results | ( @ ) The time for defervescence , duration of pharyngeal hyperemia , duration of swollen tonsils was shorter in the treatment group than in the control group ( P < @ ) . | 7 |
24672940 | results | The subsidence of lymphadenopathy , hepatomegaly , and abnormal lymphocytes was better in the treatment group than in the control group ( P < @ ) . | 8 |
24672940 | results | ( @ ) The positive cases of peripheral blood hetero-lymphocyte was significantly reduced after treatment , at week @ and @ of follow-ups both in the treatment group and the control group ( P < @ ) . | 9 |
24672940 | results | The expression of IgA and IgM decreased after treatment in the two groups when compared with before treatment in the same group ( P < @ , P < @ ) . | 10 |
24672940 | results | IgG in the treatment group also obviously decreased after treatment , at week @ and @ of follow-ups ( P < @ , P < @ ) , while it decreased only after treatment in the control group ( P < @ ) . | 11 |
24672940 | results | Activities of AST and ALT in the treatment group and the AST activity in the control group were markedly improved when compared with those before treatment ( P < @ ) . | 12 |
24672940 | results | Compared with the control group , the abnormal lymphocyte positive case number obviously decreased in the treatment group after treatment , at week @ and @ of follow-ups ( P < @ ) . | 13 |
24672940 | results | ( @ ) After treatment , at week @ and @ of follow-ups , CD@ + and CD@ + significantly decreased ; CD@ + , CD@/CD@ , and B cells significantly increased in the two groups , when compared with before treatment ( P < @ ) . | 14 |
24672940 | results | NK cells significantly increased more in the treatment group after treatment , at week @ and @ of follow-ups , higher than before treatment as well as the control group ( P < @ ) . | 15 |
24672940 | results | ( @ ) EB viral DNA and EB viral CA-IgM negative conversion case numbers significantly increased in the two groups after treatment , at week @ and @ of follow-ups ( P < @ ) . | 16 |
24672940 | results | Compared with the control group , EB viral DNA and EB viral CA-IgM negative conversion case numbers significantly increased in the treatment group after treatment and at week @ of follow-ups ( P < @ ) . | 17 |
24672940 | conclusions | Treatment of EB virus infection by Chinese medical treatment was effective . | 18 |
24672940 | conclusions | It could promote the recovery of EB viral infection , and reduce the risk of vicious disease after EB viral infection . | 19 |
25039547 | objective | The primary objective was to compare the cosmetic outcomes of traumatic trunk and extremity lacerations repaired using absorbable versus nonabsorbable sutures . | 0 |
25039547 | objective | The secondary objective was to compare complication rates between the two groups . | 1 |
25039547 | methods | This was a randomized controlled trial comparing wounds repaired with Vicryl Rapide and Prolene sutures . | 2 |
25039547 | methods | Pediatric and adult patients with lacerations were enrolled in the study . | 3 |
25039547 | methods | At a @-day follow-up , the wounds were evaluated for infection and dehiscence . | 4 |
25039547 | methods | After @ months , patients returned to have the wounds photographed . | 5 |
25039547 | methods | Two plastic surgeons blinded to the method of closure rated the cosmetic outcome of each wound using a @-mm visual analog scale ( VAS ) . | 6 |
25039547 | methods | Using a noninferiority design , a VAS score of @ mm or greater was considered to be a clinically significant difference . | 7 |
25039547 | methods | We used a Student 's t-test to compare differences between mean VAS scores and odds ratios ( ORs ) to compare differences in complication rates between the two groups . | 8 |
25039547 | results | Of the @ patients enrolled , @ completed the study including @ in the Vicryl Rapide group and @ in the Prolene group . | 9 |
25039547 | results | The mean ( SD ) age of patients who completed the study was @ ( @ ) years , and @ were male . | 10 |
25039547 | results | We found no significant differences in the age , race , sex , length of wound , number of sutures , or layers of repair in the two groups . | 11 |
25039547 | results | The observer 's mean VAS for the Vicryl Rapide group was @ mm ( @ % confidence interval -LSB- CI -RSB- = @ to @ mm ) and for the Prolene group was @ mm ( @ % CI = @ to @ mm ) . | 12 |
25039547 | results | The resulting mean difference was @ mm ( @ % CI = -@ to @ mm ; p = @ ) ; thus noninferiority was established . | 13 |
25039547 | results | Statistical testing showed no differences in the rates of complications between the two groups , but a higher percentage of the Vicryl Rapide wounds developed complications . | 14 |
25039547 | conclusions | The use of absorbable sutures for the repair of simple lacerations on the trunk and extremities should be considered as an alternative to nonabsorbable suture repair . | 15 |
25139873 | objective | Aspirin early after intravenous thrombolysis in acute ischemic stroke increases the risk of symptomatic intracranial hemorrhage ( SICH ) , without influencing functional outcome at @ months . | 0 |
25139873 | objective | The effect of aspirin on early neurological deterioration ( END ) was explored as a post hoc analysis of the randomized Antiplatelet Therapy in Combination With Recombinant t-PA Thrombolysis in Ischemic Stroke ( ARTIS ) trial . | 1 |
25139873 | methods | END , defined as a @ points National Institutes of Health Stroke Scale worsening @ hours after intravenous thrombolysis , was categorized into SICH ( ENDSICH ) and cerebral ischemia ( ENDCI ) . | 2 |
25139873 | methods | Multinomial logistic regression was used to assess the effect of aspirin on END . | 3 |
25139873 | results | Of the @ patients , @ patients ( @ % ) experienced END ( @ ENDSICH , @ ENDCI ) . | 4 |
25139873 | results | Aspirin increased the risk of ENDSICH ( odds ratio , @ ; @ % confidence interval , @-@ @ ) but not of ENDCI ( odds ratio , @ ; @ % confidence interval , @-@ @ ) . | 5 |
25139873 | results | After adjustment for other explanatory variables , the association between aspirin and ENDSICH remained significant . | 6 |
25139873 | conclusions | In this trial , there is no evidence of an early antithrombotic effect from the addition of aspirin to intravenous thrombolysis in acute ischemic stroke . | 7 |
24917273 | objective | To compare the relative effectiveness of methotrexate and mycophenolate mofetil for noninfectious intermediate uveitis , posterior uveitis , or panuveitis . | 0 |
24917273 | methods | Multicenter , block-randomized , observer-masked clinical trial . | 1 |
24917273 | methods | Eighty patients with noninfectious intermediate , posterior , or panuveitis requiring corticosteroid-sparing therapy at Aravind Eye Hospitals in Madurai and Coimbatore , India . | 2 |
24917273 | methods | Patients were randomized to receive @ mg weekly oral methotrexate or @ g twice daily oral mycophenolate mofetil and were monitored monthly for @ months . | 3 |
24917273 | methods | Oral prednisone and topical corticosteroids were tapered . | 4 |
24917273 | methods | Masked examiners assessed the primary outcome of treatment success , defined by achieving the following at @ and @ months : ( @ ) @ + anterior chamber cells , @ + vitreous cells , @ + vitreous haze and no active retinal/choroidal lesions in both eyes , ( @ ) @ mg of prednisone and @ drops of prednisolone acetate @ % a day , and ( @ ) no declaration of treatment failure because of intolerability or safety . | 5 |
24917273 | methods | Additional outcomes included time to sustained corticosteroid-sparing control of inflammation , change in best spectacle-corrected visual acuity , resolution of macular edema , adverse events , subgroup analysis by anatomic location , and medication adherence . | 6 |
24917273 | results | Forty-one patients were randomized to methotrexate and @ to mycophenolate mofetil . | 7 |
24917273 | results | A total of @ patients ( @ methotrexate , @ mycophenolate mofetil ) contributed to the primary outcome . | 8 |
24917273 | results | Sixty-nine percent of patients achieved treatment success with methotrexate and @ % with mycophenolate mofetil ( P = @ ) . | 9 |
24917273 | results | Treatment failure from adverse events or tolerability was not different by treatment arm ( P = @ ) . | 10 |
24917273 | results | There were no differences between treatment groups in time to corticosteroid-sparing control of inflammation ( P = @ ) , change in best spectacle-corrected visual acuity ( P = @ ) , or resolution of macular edema ( P = @ ) . | 11 |
24917273 | conclusions | There was no statistically significant difference in corticosteroid-sparing control of inflammation between patients receiving methotrexate or mycophenolate mofetil . | 12 |
24917273 | conclusions | However , there was a @ % difference in treatment success favoring methotrexate . | 13 |
24925006 | background | The prevalence of methicillin-resistant Staphylococcus aureus ( MRSA ) respiratory infection in cystic fibrosis ( CF ) has increased dramatically over the last decade , and is now affecting approximately @ % of patients . | 0 |
24925006 | background | Epidemiologic evidence suggests that persistent infection with MRSA results in an increased rate of decline in FEV@ and shortened survival . | 1 |
24925006 | background | Currently , there are no conclusive studies demonstrating an effective and safe treatment protocol for persistent MRSA respiratory infection in CF. | 2 |
24925006 | methods | The primary objective of this study is to evaluate the safety and efficacy of a @-day course of vancomycin for inhalation in combination with oral antibiotics in eliminating MRSA from the respiratory tract of individuals with CF and persistent MRSA infection . | 3 |
24925006 | methods | This is a two-center , randomized , double-blind , comparator-controlled , parallel-group study with @:@ assignment to either vancomycin for inhalation ( @mg twice a day ) or taste-matched placebo for @days in individuals with cystic fibrosis . | 4 |
24925006 | methods | In addition , both groups will receive oral rifampin , a second oral antibiotic - trimethoprim/sulfamethoxazole ( TMP/SMX ) or doxycycline , protocol determined - mupirocin intranasal cream , and chlorhexidine body washes . | 5 |
24925006 | methods | Forty patients with persistent respiratory tract MRSA infection will be enrolled : @ will be randomized to vancomycin for inhalation and @ to a taste-matched placebo . | 6 |
24925006 | methods | The primary outcome will be the presence of MRSA in sputum respiratory tract cultures @month after the conclusion of treatment . | 7 |
24925006 | methods | Secondary outcomes include the efficacy of the intervention on : FEV@ % predicted , patient reported outcomes , pulmonary exacerbations , and MRSA colony-forming units found in respiratory tract sample culture . | 8 |
24925006 | conclusions | Results of this study will provide guidance to clinicians regarding the safety and effectiveness of a targeted eradication strategy for persistent MRSA infection in CF. | 9 |
24559194 | background | There is a strong association between weight gain and metabolic events in patients with schizophrenia receiving many of the second-generation antipsychotic agents . | 0 |
24559194 | background | We explored the relationship between body mass index ( BMI ) and metabolic events in patients with schizophrenia receiving long-acting injectable paliperidone palmitate ( PP ) in a long-term trial . | 1 |
24559194 | methods | We conducted a post hoc analysis of data from a PP study that included a @-week open-label transition ( TR ) and maintenance phase ; a variable duration , randomized , double-blind ( DB ) , placebo-controlled phase and a @-week open-label extension ( OLE ) phase . | 2 |
24559194 | methods | Overall , @ patients received PP continuously from study entry through discontinuation or study completion and were grouped by baseline BMI ( kg/m@ ) : underweight ( BMI < @ ; n = @ , @ % ) , normal-weight ( BMI @ - < @ ; n = @ , @ % ) , overweight ( BMI @ - < @ ; n = @ , @ % ) and obese ( BMI @ ; n = @ , @ % ) . | 3 |
24559194 | methods | Metabolic treatment-emergent adverse events ( TEAEs ) and changes in related laboratory results from TR baseline were analyzed . | 4 |
24559194 | results | PP exposure was similar across BMI groups ; overall mean ( SD ) dose/month was @ ( @ ) mg eq . | 5 |
24559194 | results | -LSB- @ ( @ ) mg -RSB- ; median duration of exposure was @ days ( @ to @ days ) . | 6 |
24559194 | results | Occurrences of metabolic TEAEs overall by group were @ % ( underweight ) , @ % ( normal-weight ) , @ % ( overweight ) , and @ % ( obese ) . | 7 |
24559194 | results | The most common ( @ % ) metabolic TEAE were weight gain and elevated blood levels of glucose , lipids , and insulin . | 8 |
24559194 | results | Mean BMI and weight increased in normal-weight and overweight groups at DB endpoint , and in underweight , normal-weight and overweight groups at OLE endpoint ( p @ ) . | 9 |
24559194 | results | No consistent trend for increased metabolic-related laboratory values by baseline BMI group was observed . | 10 |
24559194 | results | Homeostatic model assessments for insulin resistance indicated preexisting insulin resistance at baseline , with minimal changes at OLE endpoint across baseline BMI groups . | 11 |
24559194 | conclusions | Occurrences of metabolic-related TEAEs trended with greater BMI status in patients with schizophrenia treated with PP ; consistent trends in metabolic-related laboratory values were not observed . | 12 |
25203483 | background | Fecal immunochemical tests ( FITs ) are recommended to screen average-risk adults for colorectal cancer ( CRC ) . | 0 |
25203483 | background | Little research has examined whether a two-sample FIT affects participant uptake , compared with a one-sample FIT . | 1 |
25203483 | background | Examining participant uptake is important , as evidence suggests that a two-sample FIT may increase the sensitivity to detect CRC . | 2 |
25203483 | objective | This study had two objectives : ( i ) to evaluate FIT completion in a population that received either a one-sample FIT kit ( @-FIT ) or a two-sample FIT kit ( @-FIT ) and ( ii ) to understand whether uptake varies by age , sex , or receipt of prior CRC screening . | 3 |
25203483 | methods | We conducted a randomized controlled trial in which @ participants who were aged between @ and @ years and were at an average risk for CRC , and who had requested FITs , randomly received @-FIT ( n = @ ) or @-FIT ( n = @ ) kits . | 4 |
25203483 | methods | FIT completion was defined as the completion and return of a one-sample test by the patients in the @-FIT group or of both sample tests by those in the @-FIT group . | 5 |
25203483 | methods | Cox proportional hazard regression models were used to determine the independent effect of group type ( @-FIT vs. @-FIT ) on the completion of the FIT , adjusting for age , sex , and receipt of prior CRC screening . | 6 |
25203483 | results | The @-FIT group had lower test completion rates ( hazard ratio = @ ; @ % confidence interval = @-@ @ ; P = @ ) after adjusting for age , sex , and receipt of prior CRC screening . | 7 |
25203483 | results | Participant uptake did not vary by age , sex , or receipt of prior CRC screening . | 8 |
25203483 | conclusions | This unique , rigorous randomized controlled trial found that the @-FIT regimen decreases completion of FIT . | 9 |
25203483 | conclusions | Further research is needed to understand whether decreases in participant uptake are offset by increased gains in test sensitivity . | 10 |
25227656 | objective | Evaluation of the safety and efficacy of pazopanib , a multikinase angiogenesis inhibitor , in a single-arm , open-label , extension study ( VEG@/NCT@ ) for placebo-treated patients with advanced renal cell carcinoma ( RCC ) from a randomized , double-blind , placebo-controlled phase III study ( VEG@/NCT@ ) . | 0 |
25227656 | methods | Patients received pazopanib @ mg/day . | 1 |
25227656 | methods | The primary endpoint was the safety and tolerability of pazopanib treatment . | 2 |
25227656 | methods | Secondary endpoints included response rate per Response Evaluation Criteria in Solid Tumors , progression-free survival ( PFS ) , and overall survival ( OS ) . | 3 |
25227656 | results | Seventy-nine placebo-treated patients from VEG@/NCT@ who experienced disease progression and one pazopanib-treated patient ( an exemption ) were enrolled . | 4 |
25227656 | results | Forty-one patients ( @ % ) were treatment-naive ; @ ( @ % ) were cytokine-pretreated . | 5 |
25227656 | results | Median exposure to pazopanib was @ months . | 6 |
25227656 | results | All patients had discontinued pazopanib at the time of analysis . | 7 |
25227656 | results | The most common reason for discontinuation was disease progression ( @ % ) . | 8 |
25227656 | results | The most common adverse events were hypertension ( @ % ) , diarrhea ( @ % ) , hair color changes ( @ % ) , anorexia ( @ % ) , and nausea ( @ % ) . | 9 |
25227656 | results | The response rate was @ % -LSB- @ % confidence interval ( CI ) : @-@ @ -RSB- ; median PFS was @ months ( @ % CI : @-@ @ ) ; median OS was @ months ( @ % CI : @-@ @ ) . | 10 |
Subsets and Splits